argenex SE $ARGX Shares Purchased by Assetmark Inc.

Assetmark Inc. increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 8.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,818 shares of the company’s stock after purchasing an additional 791 shares during the period. Assetmark Inc.’s holdings in argenex were worth $7,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Bessemer Group Inc. lifted its position in shares of argenex by 276.5% during the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after buying an additional 47 shares in the last quarter. MAI Capital Management raised its position in argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after acquiring an additional 78 shares during the period. Mather Group LLC. purchased a new position in argenex during the third quarter valued at $50,000. TD Private Client Wealth LLC grew its position in shares of argenex by 750.0% in the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after purchasing an additional 75 shares during the period. Finally, Geneos Wealth Management Inc. grew its position in shares of argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Trading Down 1.4%

Shares of NASDAQ:ARGX opened at $821.96 on Tuesday. The company has a market capitalization of $50.86 billion, a price-to-earnings ratio of 35.29, a PEG ratio of 0.71 and a beta of 0.37. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The business has a 50-day moving average price of $834.55 and a 200 day moving average price of $803.03.

Analyst Upgrades and Downgrades

ARGX has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Zacks Research lowered argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. Stifel Nicolaus increased their price objective on argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Truist Financial raised their price objective on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Finally, Wolfe Research reaffirmed a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, argenex currently has a consensus rating of “Moderate Buy” and an average price target of $986.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.